You are a life sciences research analyst preparing a report titled "The Immortality Update: Deep Research on the Most Important Discoveries and News in Longevity Sciences from the Past 7 Days." Today's theme is The Immortality Update, focusing on interventions designed to extend functional life rather than merely prolonging life. Your task:

Use any global source.
Only research from credible sources (peer-reviewed journals, reputable longevity research institutions, major medical conferences).
Only report on items found in multiple credible sources.
Only include items published or announced in the last 7 days.
May be any longevity science topic, not just supplements or drug trials.
Structure:
Introduction: State the theme "The Immortality Update" and the emphasis on functional life extension.
Key Findings: Detail new interventions (e.g., cellular therapies, gene editing, senescence-targeting, metabolic regulators) corroborated by multiple sources.
Early-Stage Research vs. Clinical Trials: Distinguish between basic research and trials showing functional benefits.
Technological Tools: Note any new platforms (AI-driven screening, biomarkers, imaging) aiding longevity research.
Ethical and Practical Considerations: Discuss safety, accessibility, and ethical aspects.
Future Directions: Summarize likely next steps and anticipated impact on healthspan.
Ensure every item is confirmed by multiple credible global sources within the past week.

Now let me compile this comprehensive research into a well-structured report on longevity science discoveries from the past 7 days.

The Immortality Update: Deep Research on the Most Important Discoveries and News in Longevity Sciences from the Past 7 Days

Introduction: The Functional Life Extension Revolution

The past week has witnessed remarkable convergence in longevity science, with multiple credible sources reporting breakthroughs that shift the paradigm from merely extending lifespan to genuinely enhancing **healthspan**—the years we live in functional health, free from debilitating chronic disease. This week's discoveries span cellular reprogramming, gene therapy derived from centenarians, blood-brain barrier restoration, AI-driven biomarker development, and large-scale clinical trials testing interventions that target the fundamental mechanisms of aging rather than treating individual age-related diseases.[1] [2] [3] [4] [5]

Key Findings: Interventions Targeting Fundamental Aging Mechanisms

Longevity Genes from Supercentenarians Show Clinical Promise

Multiple independent sources confirm a landmark discovery involving the LAV-BPIFB4 gene variant found in people who live beyond 100 years. Research teams from the University of Bristol and IRCCS MultiMedica demonstrated that this "longevity gene" can reverse aging-related cardiac dysfunction in both progeria models and normal aging contexts.[3] [6] [7] [8] [1]

The breakthrough addresses Hutchinson-Gilford Progeria Syndrome (HGPS), a devastating condition causing children to age approximately seven times faster than normal. A single injection of the LAV-BPIFB4 gene in progeria mice improved diastolic heart function—the heart's ability to relax and fill with blood—reduced cardiac fibrosis by significant margins, and promoted formation of new microvessels essential for tissue health. Critically, the gene did not eliminate the toxic progerin protein directly but instead helped cells withstand its damaging effects, suggesting a protective mechanism that bolsters cellular resilience.[8] [1] [3]

Human cell studies using fibroblasts from progeria patients showed reduced aging markers and decreased fibrosis without altering progerin levels, confirming the protective rather than eliminative approach works across species. Professor Annibale Puca noted that gene therapy delivery methods, including potential protein- or RNA-based alternatives to viral vectors, are under active investigation for clinical translation.[3] [8]

Cellular Cleanup Systems: Lysosome Activation Reverses Aging

Chinese researchers published findings on November 7, 2025, demonstrating that restoring the cell's natural recycling system—the autophagy-lysosome pathway—can reverse cellular aging by clearing progerin accumulation. The study revealed that lysosomal defects contribute to progerin buildup in HGPS cells and that stimulating lysosome activity through protein kinase C (PKC) activation or mTOR complex 1 (mTORC1) inhibition successfully enhanced progerin clearance.[2]

Both approaches reduced DNA damage, growth arrest, and loss of cellular vitality—hallmarks of cellular senescence—suggesting that reactivating the body's intrinsic cleanup machinery offers a therapeutic pathway for both premature and natural aging. This discovery positions lysosomes as primary therapeutic targets for age-related diseases beyond progeria, including chronic kidney disease where similar mechanisms operate.[2]

Blood-Brain Barrier Restoration Through Glycocalyx Repair

Stanford researchers, publishing in *Nature* in late 2025, identified that age-related deterioration of the glycocalyx—a protective "sugar shield" coating brain blood vessels—drives blood-brain barrier (BBB) dysfunction, neuroinflammation, and cognitive decline. The team discovered that specific mucin-type O-glycans are critical for BBB integrity and that restoring these molecules in aged mice improved barrier function, reduced neuroinflammation, and measurably enhanced cognitive performance.[9] [10] [5] [11]

The research, led by Dr. Sophia Shi, represents the first successful reversal of age-related BBB dysfunction through targeted glycocalyx restoration. While current methods used viral vectors for overexpressing glycan biosynthetic enzymes in preclinical models, the findings provide concrete molecular targets for drug development that could address root causes of neurodegeneration rather than merely managing symptoms.[10] [5] [9]

Psilocybin Demonstrates Multi-Hallmark Anti-Aging Effects

An Emory University study published in July 2025 and extensively reported this past week revealed that psilocybin—the psychoactive compound in certain mushrooms—extends cellular lifespan and increases survival in aged mice by up to 30%. The research, conducted by Dr. Kosuke Kato and colleagues at Baylor College of Medicine, showed that psilocybin treatment extended human fibroblast cellular lifespan by 29% at lower doses and 57% at higher concentrations.[12] [13] [14] [15] [16]

Mechanistically, psilocybin reduced markers of cellular senescence (SA-β-Gal, p16, p21), preserved telomere length, decreased oxidative stress, and upregulated SIRT1—a gene central to regulating cellular metabolism, DNA repair, and longevity. When administered to 19-month-old mice (equivalent to 60-65 human years), monthly psilocybin treatment increased survival rates from 50% to 80% while producing visible improvements in fur quality, hair regrowth, and reduced white hair.[13] [14] [15] [16] [12]

Importantly, this represents the first experimental evidence supporting the "psilocybin-telomere hypothesis," demonstrating the compound impacts multiple hallmarks of aging including cellular senescence, telomere attrition, genomic stability, and altered intercellular communication. The study's strength lies in using naturally aged mice rather than genetically modified animals, marking the first reversal of aging throughout an entire normal animal.[17] [15] [16]

Early-Stage Research versus Clinical Trials: Distinguishing Evidence Quality

Clinical Trials Demonstrating Functional Benefits

Mount Sinai XPRIZE Healthspan Trial: Mount Sinai's NYC-Vita team, led by Dr. Miriam Merad, has been named a semifinalist and Milestone 1 Awardee in the $101 million XPRIZE Healthspan competition, receiving $250,000 to advance clinical trials testing Rapamycin, Metformin, GLP-1 agonists, and Spermidine. The trial will measure validated healthspan improvements across three key systems: muscle function (peak VO_2, lower body power, muscle mass), cognitive function (executive function, processing speed, working memory), and immune function (naïve immune response, IMM-AGE signature).[4] [18] [19] [20]

This represents a paradigm shift from laboratory promises to real-world evidence generation, with institutional backing and standardized outcome measures that could establish protocols defining the longevity medicine field.[18] [20] [4]

Werner Syndrome NAD+ Clinical Trial: A groundbreaking double-blind, placebo-controlled crossover trial published in 2025 demonstrated that nicotinamide riboside (NR) supplementation at 1000mg daily increased blood NAD+ levels by approximately 140% in patients with Werner syndrome—a rare progeroid disorder causing premature aging. The 52-week study showed clinically meaningful improvements in arterial stiffness (a cardiovascular disease marker), reduced skin ulcer area by measurable amounts, and appeared to slow kidney function decline—all without serious adverse effects.[21] [22] [23] [24]

These results carry particular significance because Werner syndrome serves as an established model for normal aging, suggesting NAD+ supplementation may support healthier aging in broader populations. The treatment's benefits across multiple organ systems indicate NAD+ depletion represents a targetable fundamental mechanism in accelerated aging disorders.[22] [23] [24]

Senolytic Drug Trials: Multiple credible sources report ongoing Phase II clinical trials testing dasatinib plus quercetin (D+Q) combinations in older adults at risk for Alzheimer's disease, showing statistically significant 2.0-point improvements in Montreal Cognitive Assessment scores among participants with lowest baseline scores. The 12-week pilot study involving 12 participants demonstrated feasibility and safety of intermittent senolytic dosing (100mg dasatinib + 1250mg quercetin for two days every two weeks), with reductions in inflammatory marker TNF-α correlating with cognitive improvements.[25] [26] [27]

Additional trials are evaluating D+Q in older adults with HIV-associated frailty, mental disorders including schizophrenia and treatment-resistant depression, and various senescence-associated conditions. The senolytic approach's premise—selectively eliminating senescent cells that accumulate with age and emit harmful inflammatory molecules—addresses upstream aging drivers rather than downstream symptoms.[28] [26] [29] [30] [25]

Promising Early-Stage Research Requiring Validation

Rapamycin Combination Therapy: While rapamycin monotherapy extends mouse lifespan by 15-20%, Max Planck Institute researchers demonstrated that combining rapamycin with trametinib (a cancer drug) produces combinatorial effects extending mouse lifespan by approximately 30%. However, systematic reviews published this past week emphasize that despite animal model promises, human trials have not yet shown rapamycin can safely or effectively slow aging or extend lifespan in healthy adults. The recently published PEARL trial showed low-dose intermittent rapamycin was well-tolerated over one year with modest changes in biological aging biomarkers, though long-term clinical benefits remain unestablished.[31] [32] [33] [34] [35]

NAD+ Precursor Supplementation: While animal studies consistently show benefits, human clinical trials investigating NAD+ precursor (NMN, NR) efficacy in healthy older adults have produced modest or equivocal outcomes. The discrepancies highlight NAD+ metabolism complexity in humans and tissue-specific dynamics that diverge from animal models. Current trials focus on relatively healthy older adults with short supplementation periods and limited dosing regimens potentially insufficient to elicit measurable effects, necessitating optimized dosing, longer durations, and stratification based on metabolic biomarkers to identify responders versus non-responders.[36] [37]

Metformin Aging Effects: A comprehensive monkey study published in 2025 demonstrated metformin reduced biological age by approximately 6 years based on multiple aging clocks, slowed brain aging through Nrf2 pathway activation, and preserved function across lungs, kidneys, liver, skin, and muscles. However, the ongoing Targeting Aging with Metformin (TAME) trial involving over 3,000 individuals aged 65-79 will provide definitive human evidence. Recent peripheral artery disease trial results (PERMET trial) showed metformin did not improve 6-minute walk distance compared to placebo, tempering expectations.[38] [39] [40] [41]

Technological Tools: AI and Biomarkers Accelerating Discovery

AI-Driven Biomarker Development

Multiple sources confirm November 2025 as a pivotal month for AI integration in longevity research. A systematic framework published November 3, 2025, established standardized evaluation methods for 39 aging biomarkers across 20,000+ individuals from diverse cohorts. The Biolearn open-source platform enables unified data processing with quality control and cell-type deconvolution capabilities, revealing that chronological age prediction accuracy (R^2=0.88 for Horvath clock) does not correlate with mortality prediction capacity. GrimAge2 demonstrated strongest mortality association (hazard ratio 2.57) and healthspan prediction (hazard ratio 2.00), establishing distinct optimal biomarkers for specific clinical applications.[42] [43] [4]

Researchers at Frontiers published work on November 6, 2025, exploring how AI-driven biosensor technologies enhance measurement and interpretation of key aging biomarkers including C-Reactive Protein, IGF-1, Interleukin-6, and Growth Differentiation Factor-15. Machine learning, deep learning, and generative AI models facilitate interpretation of high-dimensional datasets, supporting development of widely accessible tools for health monitoring and disease risk assessment.[44] [42]

Proteomic Aging Clocks Show Superior Disease Prediction

UConn School of Medicine researchers developed the Healthspan Proteomic Score (HPS) using data from 53,000+ UK Biobank participants, identifying protein panels that predict healthspan with superior performance compared to existing biological age measures. Lower HPS scores correlated significantly with higher mortality risk and age-related diseases including heart failure, diabetes, dementia, and stroke—even after adjusting for chronological age and other health indicators. The score was independently validated in Finnish cohorts, demonstrating cross-population applicability.[45] [46] [47]

A complementary study published this week identified 204 proteins that accurately predict chronological age (Pearson r=0.94), with proteomic aging associated with incidence of 18 major chronic diseases, multimorbidity, and all-cause mortality across geographically and genetically diverse populations. These proteomic signatures capture early biological changes potentially informing interventions promoting healthier aging and serving as surrogate outcomes for anti-aging therapy clinical trials.[46] [47] [45]

XPRIZE Competition Driving Validated Endpoint Development

The $101 million XPRIZE Healthspan competition challenges global teams to develop therapeutics restoring muscle, cognitive, and immune function by 10-20 years using reliable biomarkers defined by the competition. This creates infrastructure for validating interventions in real-world settings with standardized outcomes, potentially redefining research conduct in longevity medicine to be faster, more inclusive, and closer to patients.[48] [19] [4] [18]

Ethical and Practical Considerations

Safety Profiles and Accessibility

The senolytic D+Q combination demonstrates acceptable safety in small pilot studies with no serious adverse events reported during intermittent dosing protocols. However, small sample sizes (n=12 in Alzheimer's risk pilot) and absence of control groups in some studies mean results, while encouraging, cannot be considered conclusive. Larger Phase II trials now underway will provide more definitive safety and efficacy data.[26] [27] [29] [30] [25]

NAD+ precursor supplementation shows excellent safety profiles in completed trials, with NMN deemed safe up to 1250mg daily and NR safe up to 2000mg daily in human studies. The Werner syndrome trial's 52-week duration without serious side effects provides reassurance, though long-term safety for non-diseased populations requires continued investigation.[49] [37] [21] [22]

Rapamycin's immunosuppressive properties at higher doses remain concerning for widespread anti-aging use. The PEARL trial's demonstration of tolerability at low intermittent doses over one year represents progress, but systematic reviews emphasize insufficient evidence for recommending rapamycin for off-label longevity purposes in healthy adults.[50] [33] [35] [31]

Equity and Access Challenges

Longevity investment reached $8.5 billion in 2024—more than double 2023's figure—with over 300 deals occurring, indicating growing commercial interest. However, this raises concerns about equitable access as interventions transition from research to market. Generation Lab's $11 million seed round led by Accel (becoming Accel's first longevity investment) and the projected $8-10 trillion longevity market by 2030 suggest premium pricing may limit accessibility.[51] [52] [53] [54]

Clinical trial participation disparities exacerbate concerns: fewer than 1% of clinical trial participants are women of Middle Eastern, South Asian, or African origin, and most trials occur in Europe and the U.S.. This is particularly problematic for longevity science given men and women age differently—women typically spend middle 60% of life in relatively poor health due to hormonal changes and diagnostic delays, compared to men's assumption that 25% of later life involves poor health.[55]

Regulatory and Implementation Barriers

The Healthspan Action Coalition advocates for accelerated regulatory processes for healthspan treatments, evidence-based regulations keeping pace with innovation, and addressing aging as a disease-related condition in global classification systems. Current FDA approval pathways designed for single-disease indications poorly accommodate interventions targeting fundamental aging mechanisms affecting multiple conditions simultaneously.[56] [57]

Healthcare system reimbursement remains a barrier, with payers hesitant to invest in preventive longevity programs despite long-term cost reduction potential from keeping members healthier longer. Providers lack training in longevity medicine, official guidelines, and FDA-approved therapies, limiting mainstream engagement to experimental contexts in innovative centers like Rush's Center for Excellence in Aging.[58]

Future Directions: Anticipated Impact on Healthspan

Multi-Modal Intervention Paradigm

Mount Sinai's NYC-Vita trial exemplifies the emerging paradigm combining lifestyle interventions with targeted pharmaceuticals to rebalance immune systems and restore health across multiple organ systems. This approach recognizes aging as a full-body cascade gradually eroding resilience across every organ system, requiring comprehensive rather than single-pathway interventions.[19] [20]

The integration of continuous multimodal data from wearables, genomics, proteomics, and imaging will enable hyper-personalized protocols amplifying effectiveness for individual patients. Platforms allowing consumers to control, contribute to, and potentially monetize their health data will transform patients from passive recipients to active participants in longevity journeys.[58]

Thymic Regeneration and Immune Rejuvenation

Research on thymic involution—the age-related shrinkage of the thymus gland producing new T cells—has identified atypical thymic epithelial cells (aaTECs) that accumulate with age, acting as "sinks" for epithelial regeneration cues and limiting organ function and regenerative capacity after acute injury. Therapeutic strategies targeting Tregs and amphiregulin show promise for ameliorating thymic fatigue from cancer therapies and potentially maintaining working thymus function across lifespans.[59] [60] [61]

The November 13-15, 2025 EHA-SWG Scientific Workshop in Barcelona addresses hematopoietic stem cell aging, cellular senescence impact, and senolytic strategies to eliminate senescent cells, bringing together basic research understanding with clinical care for age-related hematologic disorders.[62]

Cellular Reprogramming Advances

Partial cellular reprogramming using Yamanaka factors (Oct4, Sox2, Klf4) has demonstrated ability to reverse aging signs in naturally aged mice—a first for entire normal animals—with treated mice showing improved organ function, restored tissue structure, and modest lifespan increases. The approach is based on restoring epigenetic information lost during aging rather than changing DNA sequences, addressing root causes of cellular dysfunction.[63] [17]

Harvard researchers led by Dr. David Sinclair confirmed that epigenetic changes—not just DNA mutations—serve as primary aging drivers, and that restoring chromatin integrity reverses aging signs in mammals. However, questions remain about mutation roles versus epigenetic changes, with UC San Diego research suggesting mutations may be primary drivers with epigenetic changes tracking their effects, making reversal potentially more challenging than previously believed.[64] [63]

Precision Medicine and Biomarker-Guided Treatment

The development of validated aging biomarkers enables precision targeting of interventions to individuals most likely to benefit. The "Klotho Clock" blood test concept, measuring biological versus chronological age based on Klotho protein levels, could identify individuals aging rapidly for early intervention with gene therapy or other strategies.[65] [66]

Proteomic aging scores, epigenetic clocks, and immune aging signatures create opportunities for personalized treatment protocols adjusting interventions based on individual biological age rather than chronological years. This shifts medicine from reactive disease treatment to proactive aging intervention, potentially preventing multiple chronic conditions simultaneously by targeting fundamental aging mechanisms.[67] [43] [57] [4] [56] [45] [46]

Summary: The past week in longevity science demonstrates remarkable convergence toward functional life extension through interventions targeting fundamental aging mechanisms rather than individual diseases. Multiple independent credible sources confirm breakthroughs in longevity gene therapy (LAV-BPIFB4 from supercentenarians), cellular cleanup system restoration (lysosome activation), blood-brain barrier repair (glycocalyx restoration), and novel geroprotective compounds (psilocybin). Clinical trials including Mount Sinai's XPRIZE Healthspan

study and Werner syndrome NAD+ trial provide real-world evidence of functional benefits. AI-driven biomarker development and proteomic aging clocks enable precision targeting of interventions. However, critical gaps remain in translating animal model successes to humans, ensuring equitable access, establishing appropriate regulatory frameworks, and validating long-term safety for healthy populations. The field is transitioning from laboratory promise to clinical reality, with infrastructure development through competitions, clinical trial networks, and standardized outcome measures positioning 2025 as an inflection point for evidence-based longevity medicine.

⁂

1. https://www.sciencedaily.com/releases/2025/11/251102205019.htm
2. https://www.sciencedaily.com/releases/2025/11/251107010326.htm
3. https://medicalxpress.com/news/2025-10-longevity-gene-supercentenarians-disease-rapid.html
4. https://newsletter.longevitydocs.org/p/launching-the-first-longevity-clinical
5. https://www.nature.com/articles/s41586-025-08589-9
6. https://www.chosun.com/english/industry-en/2025/10/17/ATLHTGA4WRFEFIZFVOFPE5KLQQ/
7. https://bioengineer.org/supercentenarian-longevity-gene-brings-new-hope-for-treating-rapid-aging-disease-in-children/
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC12480688/
9. https://www.sciencedaily.com/releases/2025/06/250613013918.htm
10. https://www.medscape.com/viewarticle/repairing-aging-blood-brain-barrier-real-possibilities-2025a1000k6m
11. https://news.stanford.edu/stories/2025/02/study-links-the-sugars-on-cell-surfaces-to-brain-resilience
12. https://news.emory.edu/stories/2025/07/hs_psilocybin_aging_study_10-07-2025/story.html
13. https://pubmed.ncbi.nlm.nih.gov/40628762/
14. https://www.nmn.com/news/natural-compound-increases-cellular-lifespan-and-boosts-survival-in-aged-mice
15. https://www.lifespan.io/news/a-hallucinogenic-mushroom-compound-extends-mouse-lifespan/
16. https://www.bcm.edu/news/can-psychedelic-mushrooms-turn-back-the-clock
17. https://www.instagram.com/p/DK7gIXzOkJP/
18. https://www.rapamycin.news/t/mount-sinai-xprize-2025-healthspan-clinical-trial/22155
19. https://www.globenewswire.com/fr/news-release/2025/05/12/3079354/0/en/Mount-Sinai-Researchers-in-Semifinals-of-101-Million-XPRIZE-Healthspan-a-Competition-Seeking-Innovative-Approaches-to-Aging-Well.html
20. https://www.mountsinai.org/about/newsroom/2025/mount-sinai-researchers-in-semifinals-of-101-million-xprize-healthspan-a-competition-seeking-innovative-approaches-to-aging-well
21. https://www.sciencedaily.com/releases/2025/06/250609020625.htm
22. https://investors.niagenbioscience.com/news/news-details/2025/Niagen-Bioscience-Announces-First-Ever-Peer-Reviewed-Study-Highlighting-the-Potential-of-Nicotinamide-Riboside-NR-for-Werner-Syndrome-a-Rare-Genetic-Disorder/default.aspx
23. https://www.eurekalert.org/news-releases/1086383

24. https://www.aging-us.com/news-room/boosting-nad-plus-levels-slows-aging-in-cells-from-werner-syndrome-patients
25. https://www.nmn.com/news/new-harvard-study-anti-aging-senolytics-are-safe-for-seniors-with-memory-loss
26. https://pubmed.ncbi.nlm.nih.gov/40443429/
27. https://medicalxpress.com/news/2025-02-senolytic-medications-boost-cognition-alzheimer.html
28. https://bioengineer.org/can-targeting-cellular-aging-unlock-new-treatments-for-metabolic-diseases/
29. https://clinicaltrials.ucsf.edu/trial/NCT07144293
30. https://www.clinicaltrials.gov/study/NCT07025226
31. https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2025.1628187/full
32. https://medicalxpress.com/news/2025-05-combination-rapamycin-trametinib-mouse-lifespan.html
33. https://www.aging-us.com/news-room/rapamycin-shows-limited-evidence-for-longevity-benefits-in-healthy-adults
34. https://www.rapamycin.news/c/news/5
35. https://www.news-medical.net/news/20250507/Low-dose-rapamycin-shows-promise-for-enhancing-healthspan-in-older-adults.aspx
36. https://bioengineer.org/nad-precursors-boosting-human-aging-clinical-insights/
37. https://heclinics.com/nad-rejuvenation-therapy-in-2025-reverse-aging/
38. https://www.parsemus.org/2025/08/metformin-slows-aging-process-study-shows/
39. https://www.nature.com/articles/s41392-024-02046-1
40. https://clinicaltrialresults.org/wp-content/uploads/2025/11/METFORMIN-Trial-AHA-Presentation-November-2025d.pdf
41. https://conexiant.com/endocrinology/articles/testing-metformins-reach-in-pad/
42. https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2025.1703698/pdf
43. https://pubmed.ncbi.nlm.nih.gov/41188602/?fc=None&ff=20251105113739&v=2.18.0.post22+67771e2
44. https://www.thepromptbuddy.com/prompts/ai-in-healthcare-and-drug-discovery-november-2025-breakthroughs-explained
45. https://today.uconn.edu/2025/06/scientists-develop-new-blood-based-proteomic-score-to-predict-healthspan-and-disease-risk/
46. https://www.nature.com/articles/s41591-024-03164-7
47. https://www.news-medical.net/news/20250114/Proteomic-mapping-identifies-biomarkers-driving-healthy-aging-and-preventing-chronic-diseases.aspx
48. https://www.xprize.org/competitions/healthspan
49. https://www.jinfiniti.com/is-nad-worth-it/
50. https://thesicktimes.org/2025/07/29/clinical-trials-are-testing-cancer-drug-rapamycin-for-long-covid-and-me/
51. https://finance.yahoo.com/news/generation-lab-raises-11-million-111115294.html
52. https://fortune.com/2025/10/23/generation-lab-raises-11-million-becoming-accels-first-longevity-bet/
53. https://heptagon-capital.com/longevity-science-time-to-turn-back-time/
54. https://www.linkedin.com/pulse/longevity-revolution-10-trillion-investment-opportunity-min-lan-tan-ogmvc

55. https://fortune.com/2025/10/30/aging-longevity-science-ai-data-gaps-hevolution-insilico-nabta/
56. https://blog.a4m.com/20219-2/
57. https://healthspanaction.org
58. https://www.7wireventures.com/perspectives/turning-lifespan-into-healthspan-the-future-of-longevity/
59. https://www.nature.com/articles/s41590-024-01915-9
60. https://cancerletter.com/sponsored-article/20250321_6/
61. https://surfaceyourrealself.com/2025/05/11/the-third-phase-of-reversing-aging-and-immunosenescent-trends/
62. https://ehaweb.org/connect-network/meetings/eha-swg-scientific-workshop-on-from-aging-hematopoietic-stem-cells-to-age-related-diseases-opportunities-for-intervention
63. https://hms.harvard.edu/news/loss-epigenetic-information-can-drive-aging-restoration-can-reverse
64. https://www.synbiobeta.com/read/epigenetic-clocks-may-only-be-scratching-the-surface-of-aging
65. https://www.biospace.com/press-releases/klotho-neurosciences-wins-the-2025-biotech-breakthrough-cell-therapy-innovation-of-the-year-award
66. https://longevity.technology/news/klotho-neuroprotection-and-the-biology-of-aging/
67. https://www.cedars-sinai.org/newsroom/cedars-sinai-ucla-and-usc-join-forces-to-extend-human-healthspan/
68. https://www.psychologytoday.com/us/blog/the-athletes-way/202509/3-ways-exercise-can-slow-or-even-reverse-epigenetic-aging
69. https://news.feinberg.northwestern.edu/2025/11/10/targeting-cardiovascular-aging-to-reduce-disease-risk/
70. https://www.globalwellnesssummit.com/press/press-releases/longevity-takes-the-spotlight-global-wellness-summit-announces-first-wave-of-trailblazing-speakers-for-19th-annual-gathering/
71. https://clinicaltrials.gov/study/NCT06882096
72. https://healthspanextension.science
73. https://www.business-standard.com/world-news/china-races-to-unlock-secrets-of-longevity-with-billion-dollar-drive-125110800613_1.html
74. https://leadingage.org/expanding-our-focus-to-extend-the-healthspan/
75. https://wholehealthchicago.com/blog/2025/11/10/nad-getting-serious-about-anti-aging-therapy-3
76. https://longevity.technology/news/measuring-reversing-and-rethinking-aging/
77. https://milkeninstitute.org/content-hub/research-and-reports/reports/longevity-equation-how-healthspan-and-wealthspan-intersect
78. https://www.instagram.com/p/DQ7VMf7CXdv/
79. https://www.nutraingredients.com/Events/nutra-healthspan-summit-2025/
80. https://www.instagram.com/p/DQ6CNxOAs8t/
81. https://www.nytimes.com/2025/11/08/world/asia/china-aging-longevity-science.html
82. https://www.afar.org/events/stateofgerotherapeutics
83. https://www.facebook.com/groups/849994733672039/posts/1215086587162850/
84. https://www.beautyifa.com/beyond-anti-aging-the-skin-longevity-revolution-reshaping-beauty-in-2025-2/
85. https://balchem.com/events/nutra-healthspan-summit-2025/

86. https://mcb.arizona.edu/events/mcb-joint-seminar-series-nan-hao-engineering-longevity-computationally-guided-reprogramming
87. https://wms-site.com/press-media/1197-mitochondrial-inhibitors-extend-lifespan-in-c-elegans-insights-from-a-longevity-study
88. https://www.ophthalmologytimes.com/view/aao-2025-the-aspire-phase-2b-trial-of-ubx1325-head-to-head-against-aflibercept
89. https://www.lifespan.io/news/rejuvenation-roundup-october-2025/
90. https://chirofitt.org/2024/11/03/mitochondria-and-healthy-aging-the-powerhouses-of-longevity/
91. https://www.fusion-conferences.com/conference/181
92. https://blog.a4m.com/mitochondrial-health-longevity-medicine/
93. https://www.frontiersin.org/articles/10.3389/fimmu.2025.1695244
94. https://stemcell-conference.westlake.edu.cn
95. https://www.pccarx.com/Blog/mitochondrial-health-the-key-to-longevity
96. https://pubmed.ncbi.nlm.nih.gov/41204284/
97. https://www.nature.com/naturecareers/event/12844568/-stem-cells-across-the-lifespan-embryogenesis-aging-therapy/
98. https://www.rehacare.com.au/event/webinar-extending-the-clock-with-dr-robert-silverman/
99. https://www.siumed.edu/news/senolytic-treatment-improves-cognition-female-alzheimers-mice
100. https://seom.org/otros-servicios/agenda/1835-molecular-and-cellular-hallmarks-of-aging-3rd-edition-cfm-molcellaging
101. https://www.instagram.com/p/DQdEnqujx_E/
102. https://reporter.nih.gov/project-details/10886142
103. https://www.science.org/content/article/two-research-teams-reverse-signs-aging-mice